Baseline and the changes of neutrophil-to-lymphocyte ratio throughout chemoradiotherapy in nasopharyngeal cancer
Active, not recruiting
- Conditions
- asopharyngeal cancernasopharyngeal cancerNPCneutrophil to lymphocyte ratiochemoradiotherapyNLRinflammatorysurvival
- Registration Number
- TCTR20220810006
- Lead Sponsor
- Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 81
Inclusion Criteria
1. age 18-70 years old
2. histology-proven WHO type 2 NPC, stage T2N0M0-T4N2M0 (AJCC 7th edition)
3. Eastern Cooperative Oncology Group performance status 0-1
4. adequate bone marrow function, and serum creatinine clearance not less than 30 mL per min
Exclusion Criteria
N3 or metastatic disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eutrophil-to-lymphocyte ratio Start concurrent chemoradiotherapy Blood test,Neutrophil-to-lymphocyte ratio End of concurrent chemoradiotherapy Blood test,Neutrophil-to-lymphocyte ratio End of adjuvant chemotherapy Blood test
- Secondary Outcome Measures
Name Time Method Overall survival Last visit Patient status from medical records